<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058054</url>
  </required_header>
  <id_info>
    <org_study_id>KSCM-CRD-002</org_study_id>
    <nct_id>NCT04058054</nct_id>
  </id_info>
  <brief_title>Skin Prick Test of KeraStat® Cream</brief_title>
  <official_title>Skin Prick Test of KeraStat® Cream</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KeraNetics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KeraNetics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the potential for a humoral reaction to KeraStat Cream compared to a predicate&#xD;
      device using the skin prick test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Overview:&#xD;
&#xD;
      Study Periods:&#xD;
&#xD;
      The length of study participation for a subject is about 2-3 days depending on availability&#xD;
      for the final site check. There are two skin prick site checks during the course of Day 1&#xD;
      with a final follow up between Days 2 and 3.&#xD;
&#xD;
      Study Evaluations:&#xD;
&#xD;
      Initial screening (Screening Visit; Visit 1) will be performed on the day of the Skin Prick&#xD;
      Test (SPT) administration and will include obtaining demographic information, brief medical&#xD;
      history, and abbreviated physical exam.&#xD;
&#xD;
      On Day 1 (Visit 1) the SPT will be performed on the infrascapular region of the back to the&#xD;
      right of the midline. Test articles will include the subject device (KeraStat Cream),&#xD;
      predicate devices (KeraStat Gel, Biafine), positive control (histamine), and negative control&#xD;
      (saline). Each test article will have a single administration, only the re-test will utilize&#xD;
      a triplicate administration. The SPT will be ready for initial reading after approximately 15&#xD;
      minutes (but no sooner than 10 minutes and no longer than 20 minutes) following the final SPT&#xD;
      administration in the series. When reading the test, the investigator will note the presence&#xD;
      or absence of a wheal at all five sites and will measure the diameter of each wheal present.&#xD;
      In order for the SPT to be valid, the wheal at the positive control site must exceed that at&#xD;
      the negative control by 4 mm. If the above criteria are not met, the SPT will be repeated in&#xD;
      triplicate on the infrascapular region of the back to the left of the midline, following the&#xD;
      same protocol. Following the initial reading, the subject will remain at the testing&#xD;
      facility.&#xD;
&#xD;
      A second reading will be conducted approximately 6 hours (+/- 15 minutes) after SPT&#xD;
      administration on Day 1 (Visit 1). When reading the test, the investigator will note the&#xD;
      presence or absence of a wheal at all five sites and will measure the diameter of each wheal&#xD;
      present. Subjects are free to leave the clinical site after the second reading. Subjects will&#xD;
      be instructed to promptly contact the PI and go to the ER if symptoms of an allergic reaction&#xD;
      or shock occur.&#xD;
&#xD;
      Subjects will return to the office one to two days after initial administration for a third&#xD;
      test reading (Visit 2). When reading the test, the investigator will note the presence or&#xD;
      absence of a wheal in all five sites and will measure the diameter of each wheal present.&#xD;
      Each site of test article administration will be measured for a positive reaction. A positive&#xD;
      reaction is present when there is a measurable wheal of 3 mm or more, surrounded by a flare.&#xD;
      Small wheals are to be confirmed by palpation. A flare alone is disregarded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Actual">August 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction to test article</measure>
    <time_frame>15 minutes</time_frame>
    <description>Wheal measurement in millimeters (mm)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>KeraStat® Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KeraStat® Cream is a non-sterile, non-implantable wound dressing intended to provide a moist environment in the management of a variety of partial thickness dermal wounds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KeraStat® Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KeraStat® Gel is a sterile, non-implantable water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biafine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Wound dressing for management of partial and full thickness wounds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Histamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Histamine is provided as a solution of histamine base (6.0 mg/mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Saline (sterile) is provided as a 0.9% NaCl solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KeraStat® Cream</intervention_name>
    <description>Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.</description>
    <arm_group_label>KeraStat® Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KeraStat Gel</intervention_name>
    <description>Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.</description>
    <arm_group_label>KeraStat® Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biafine</intervention_name>
    <description>Administered 0.025 gm of Biafine per subject on day 1 of the study.</description>
    <arm_group_label>Biafine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histamine</intervention_name>
    <description>Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.</description>
    <arm_group_label>Histamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (0.9% NaCl)</intervention_name>
    <description>Administered 1 drop of saline per subject on day 1 of the study.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Sodium Chloride syringe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, age 18-65&#xD;
&#xD;
          2. Able to understand the informed consent and provide written informed consent&#xD;
&#xD;
          3. Healthy, unmarked skin at the test area&#xD;
&#xD;
          4. Agreement to avoid consumption of antihistamines until completion of third test&#xD;
             reading (Visit 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant, lactating/nursing or plan to become pregnant&#xD;
&#xD;
          2. Presence of skin disease, such as widespread urticaria or eczema&#xD;
&#xD;
          3. Diagnosis of infectious disease&#xD;
&#xD;
          4. Receiving corticosteroids, immunosuppressive agents, radiation or chemotherapy,&#xD;
             topical growth factors, anxiolytics, imipramine, phenothiazine, dopamine, phenergen,&#xD;
             clonidine, montelukast, immunotherapy, UV light therapy, H-2 antagonist, cyclosporine&#xD;
             or any other medication the investigator feels will affect the test within the last&#xD;
             month&#xD;
&#xD;
          5. Medical history of hypotension, severe hypertension, vasomotor instability, asthma,&#xD;
             autoimmune disease, severe cardiac, pulmonary or renal disease&#xD;
&#xD;
          6. Tattoo in the intrascapular test area&#xD;
&#xD;
          7. History of surgical procedure/skin graft in the intrascapular test area&#xD;
&#xD;
          8. Employee or relative of employee of KeraNetics&#xD;
&#xD;
          9. Consumption of an anti-histamine within 7 days of the screening visit&#xD;
&#xD;
         10. History of hypersensitivity to histamine products&#xD;
&#xD;
         11. Any condition the investigator determines will compromise subject safety or prevent&#xD;
             the subject from completing the study&#xD;
&#xD;
         12. Participated in an investigational study within 30 days of the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan P Wilson, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PMG Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 5, 2021</submitted>
    <returned>October 1, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

